AbbVie deal for Allergan not about the taxes thanks to 2017 law

But if the $63 billion deal for Allergan that AbbVie announced Tueday goes through, the combined company would stay in the U.S. -- a departure from both AbbVie's nixed Shire bid and Pfizer's failed attempt to buy the Irish Botox maker in 2015.